Why Is agilon health (AGL) Stock Down -14% Today?
Key Takeaways
-
Shares of AGL are declining approximately 14% in Tuesday's session on April 21, 2026, falling from a prior close of $28.30 to approximately $24.34, as mounting structural headwinds in the Medicare Advantage value-based care sector and broader healthcare market turbulence weigh heavily on investor sentiment.
-
The primary driver is a confluence of sector-wide Medicare Advantage utilization and cost pressures — agilon health explicitly guided for 7.5% cost trend growth in 2026 during its March 2026 Barclays conference presentation, directly compressing the company's path toward profitability.
-
The stock is still recovering from its March 30, 2026 completion of a 1-for-25 reverse stock split — executed to regain NYSE minimum bid price compliance — which underscores the depth of the company's ongoing financial challenges and may be triggering continued post-split selling pressure.
-
Morningstar's fair value estimate of $5.31 per share implies AGL is currently trading at a significant premium to assessed intrinsic value even at today's depressed levels, a disconnect that continues to generate bearish analyst commentary.
-
Broader healthcare sector weakness, with Medicare Advantage insurers including UnitedHealth Group (UNH) and Humana (HUM) facing their own cost-trend headwinds, is contributing to sector-wide de-rating pressure that flows through directly to agilon's value-based care model.
-
Traders will focus on AGL's Q1 2026 earnings release on May 6, 2026 and any updated guidance on the path to free cash flow break-even by 2027.
Opening Summary
agilon health, inc. (AGL) is a Westerville, Ohio-based healthcare technology and services company that partners with primary care physician groups to manage Medicare Advantage patients under a total cost of care model — meaning the company assumes financial risk for the full spectrum of patient medical expenses under capitated payment arrangements. Shares are declining approximately 14% on Tuesday, April 21, 2026, falling from a prior close of $28.30 to approximately $24.34 in elevated volume trading. The selloff extends a prolonged de-rating driven by structurally elevated Medicare Advantage medical cost trends, a damaged balance sheet, and deteriorating investor confidence following the company's March 2026 reverse stock split executed to maintain NYSE listing compliance.
Medicare Advantage Cost Trends and Structural Pressure
The fundamental force driving AGL lower is the company's own cost trend guidance, which signals ongoing profitability challenges throughout 2026. At the Barclays 28th Annual Global Healthcare Conference in March 2026, agilon management projected medical cost trend growth of 7.5% in 2026 — a level that, given the capitated nature of its payer contracts, directly erodes the company's per-member margins. The structural issue is the downstream propagation of Medicare Advantage bid mis-pricing: when major MA payers including UnitedHealth Group (UNH) and Humana (HUM) underprice their bids relative to actual utilization, and then pass financial risk to agilon through capitated contracts, agilon absorbs the resulting margin compression. This dynamic is not new, but the 2026 cost trend projection confirms that the resolution timeline extends further than investors had hoped, keeping AGL in a structurally loss-generating position through at least year-end.
Reverse Stock Split Overhang and Valuation Concerns
The March 30, 2026 completion of a 1-for-25 reverse stock split — the company's bid to bring its share price above the $1.00 minimum required by NYSE listing standards — continues to generate persistent selling pressure. Reverse splits executed for compliance purposes, rather than for strategic financial engineering, are widely understood by investors as a signal of acute financial distress, and agilon's choice of the maximum permitted 1-for-25 ratio underscored the severity of its pre-split price deterioration. Post-split, AGL opened March 31 at an adjusted price of approximately $25, but the artificial repricing has done little to change the underlying fundamentals that drove the stock to sub-$1.00 territory. Morningstar's fair value assessment of $5.31 per share — compared to today's trading price near $24 — reflects a market that continues to price in speculative recovery potential well ahead of demonstrated financial improvement.
Broader Healthcare Sector Weakness
Today's AGL decline is occurring in tandem with broad pressure across the Medicare Advantage and managed care sector. UnitedHealth Group (UNH) and Humana (HUM) have both flagged elevated medical loss ratios and rising utilization costs in recent quarters, and the broader sector is grappling with a structural reset of MA reimbursement rates and demographic utilization pressures as the Medicare-enrolled population ages. For agilon, which is entirely dependent on MA contracting for its revenue base, the deterioration in the MA economics of its payer partners is a direct and ongoing headwind. Additionally, a broadly risk-off market tone in Tuesday's session — with the S&P 500 and Nasdaq under pressure amid macroeconomic uncertainty — is amplifying selling in high-risk, pre-profitability healthcare names.
Market Context and Trading Activity
Volume in AGL on April 21 is tracking well above its recent 30-day average as institutional repositioning continues following the stock's reverse split and ongoing guidance disappointments. The Health Care Select Sector SPDR ETF (XLV) is under broad pressure in Tuesday's session, confirming sector-wide directional selling that compounds AGL's company-specific headwinds. Technically, AGL has broken below its post-split support levels, and with a 52-week range (on a split-adjusted basis) of $17.75 to $119.50, the current trading price near $24 places the stock in the lower portion of its adjusted annual range. The absence of a near-term positive catalyst — with earnings not due until May 6 — removes a near-term recovery trigger and leaves the stock subject to ongoing selling pressure in a risk-off environment.
Trending AI Robots
For traders navigating macro-driven healthcare sector selloffs and company-specific distress situations like today's decline in AGL, Tickeron's Trending AI Robots page highlights the platform's strongest-performing AI trading bots under current market conditions. Tickeron operates hundreds of AI-driven bots covering thousands of tickers, but only those demonstrating the highest real-time performance are featured in this curated section. Bots span a wide range of strategy types, holding timeframes, risk profiles, performance metrics, and traded symbol universes — from reversal and mean-reversion systems suited for high-volatility healthcare equities to more systematic, sector-agnostic approaches designed for broader market environments. Whether you are looking to manage exposure to volatile turnaround situations or identify structured opportunities elsewhere, the Trending AI Robots page is a practical and informative starting point.
What Comes Next for AGL
The most critical near-term event for AGL is its Q1 2026 earnings release, scheduled for after market close on Wednesday, May 6, 2026, followed by a conference call at 4:30 p.m. ET. This print will provide the first comprehensive financial update since the reverse stock split and will be the first opportunity for management to update investors on whether the 2026 medical cost trend trajectory is improving, stable, or worsening relative to the 7.5% growth projection disclosed at the March 2026 Barclays conference. Analysts will focus on medical loss ratio trends, membership count changes, and any update to the company's free cash flow break-even target of 2027. The company has also highlighted a $125 million expected benefit from contracting improvements — investors will monitor the pace of realization of that benefit. Key risks include further deterioration in MA payer bid adequacy, continued operating losses depleting cash reserves, potential for another compliance issue with NYSE listing standards if the stock's post-split price erodes further, and the structural challenge of achieving sustainable profitability in an environment of persistently elevated Medicare utilization.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
AGL's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for AGL turned positive on October 05, 2026. Looking at past instances where AGL's MACD turned positive, the stock continued to rise in 38 of 44 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where AGL's RSI Indicator exited the oversold zone, 35 of 43 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 51 of 60 cases where AGL's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
Following a +2.43% 3-day Advance, the price is estimated to grow further. Considering data from situations where AGL advanced for three days, in 231 of 276 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
AGL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 21, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AGL as a result. In 69 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AGL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for AGL entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 34 (best 1 - 100 worst), indicating steady price growth. AGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.869) is normal, around the industry mean (208.195). P/E Ratio (0.000) is within average values for comparable stocks, (175.456). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.005) among similar stocks. P/S Ratio (0.253) is also within normal values, averaging (2.688).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AGL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 89, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry HospitalNursingManagement
Advertisement